個別化ネオアンチゲンワクチン療法において 免疫反応を起こしやすいネオアンチゲンの特徴を解明

ad

2026-06-09 医薬基盤・健康・栄養研究所

国立研究開発法人医薬基盤・健康・栄養研究所、がん研究会、福岡がん総合クリニックの共同研究グループは、個別化ネオアンチゲン樹状細胞ワクチン療法を受けた352人のがん患者のデータを解析し、免疫反応を引き起こしやすいネオアンチゲンの特徴を明らかにした。解析対象となった2,317種類のネオアンチゲンのうち313種類(13.5%)で、ワクチン投与後にCD8陽性T細胞による免疫応答が確認された。さらに、免疫反応を誘導しやすいネオアンチゲンは、水になじみにくい疎水性が高く、HLA分子に強く結合し、細胞表面に提示されやすいという共通した特徴を持つことが判明した。これら複数の性質を組み合わせて評価することで、有効なネオアンチゲンをより高精度に予測できる可能性が示された。本研究は実際の患者データを用いた世界最大級の解析の一つであり、個々の患者に最適化したがん免疫療法の開発や治療効果向上に重要な知見を提供する成果である。

<関連情報>

がん患者における個別化ネオアンチゲンワクチンによって誘導される免疫原性ネオアンチゲンペプチドのプロファイリング Profiling immunogenic neoantigen peptides elicited by personalized neoantigen vaccine in cancer patients

Peng Zhao ,Clara Effenberger,Saki Matsumoto,Takafumi Morisaki,Yu Ishii,Masayo Umebayashi,Hiroto Tanaka,Norihiro Koya,+ 4 more,Kazuma Kiyotani
Frontiers in Immunology  Published:09 June 2026
DOI:https://doi.org/10.3389/fimmu.2026.1829509

個別化ネオアンチゲンワクチン療法において 免疫反応を起こしやすいネオアンチゲンの特徴を解明

Abstract

Introduction:

Personalized neoantigen vaccines can induce antitumor T cell responses, but only 10-20% of selected peptides have induced immune responses in patients, underscoring the limitations of current prediction strategies.

Methods:

We analyzed a clinically annotated dataset from 352 cancer patients who received personalized neoantigen peptide-pulsed dendritic cell vaccines. We focused on 2,317 short peptides derived from single nucleotide variants for which post-vaccination T cell responses were evaluated by IFN-γ ELISPOT assay. Immunogenic neoantigen peptides were defined as those inducing a ≥2.0-fold increase in IFN-γ ELISPOT responses after vaccination. We systematically examined peptide intrinsic characteristics and physicochemical properties, as well as predicted scores related to antigen-processing machinery.

Results and discussion:

Immunogenicity was not associated with specific mutation positions or sequence patterns but was significantly correlated with higher hydrophobicity (P = 5.2 × 10-4). Among several predictive scores, peptides with higher binding affinity to HLA molecules (P = 0.0014 for NetMHC3, P = 0.028 for MHCflurry-affinity), higher binding stability (P = 0.043 for NetMHCstab) or better peptide presentation scores (P = 0.012 for mixmhcPred3, P = 0.0085 for MHCflurry-presentation) were significantly enriched among immunogenic neoantigen peptides. Composite models integrating peptide physicochemical features, particularly hydrophobicity, with prediction scores improved the area under the receiver operating characteristic curve and balanced accuracy compared with individual tools alone. Together, these findings highlight the multifactorial determinants of neoantigen immunogenicity and support the integration of complementary peptide features to refine neoantigen prioritization for personalized vaccines and T cell-based immunotherapies.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました